Early hepatocellular carcinoma: findings of contrast-enhanced sonography

Kazushi Numata(Yokohama City University Medical Center), Katsuaki Tanaka(Yokohama City University Medical Center), Masaaki Kondo(Yokohama City University Medical Center), Hiroyuki Fukuda(Yokohama City University Medical Center), Akito Nozaki(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Masayuki Nakano(Nihon University), Akinori Nozawa(Yokohama City University Medical Center)
Kanzo
January 1, 2011
10.2957/kanzo.52.429
Cited by 2

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333